Views of Pharmacists and Government Representatives Toward the Pilot Chief Pharmacist System in Chinese Hospitals: A Multicenter Exploratory Qualitative Study.
China
chief pharmacist system
health system
pharmaceutical service
qualitative study
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
03
2022
accepted:
09
05
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
7
7
2022
Statut:
epublish
Résumé
In China, the pharmacy departments of most hospitals have changed their main focus from drug procurement and distribution to providing pharmaceutical care services. Various regions of China have successively implemented the pilot Chief Pharmacist System (CPS) to help improve pharmaceutical care services and rational drug use in hospitals. This study was designed to explore the perspectives of pharmacists and government officials on CPS, including the advantages and barriers to the successful implementation of CPS. A qualitative study, based on semi-structured interviews, was conducted from October 1, 2018 to March 1, 2019. The interview data were gathered from 18 pharmacy staff and government representatives working in five distinct regions of China using purposive sampling. A thematic analysis approach and NVivo version 12 Plus was utilized to code and analysis of all interviews. Five broad themes were identified: the role of the chief pharmacist; their attitudes toward the CPS; the advantages and results of the CPS; the barriers toward CPS; and their suggestions toward CPS. Most of the participants believed that the chief pharmacist played a vital role in a hospital. Under CPS, the hospital pharmacy department pays more attention to prescription review, medication monitoring, and pharmaceutical consultation. However, an insufficient number of pharmacy personnel, unclear authority, and inadequate salaries were the main barriers to the implementation of the CPS. The attitudes of most of the participants were found to be positive toward CPS in China. The CPS can enhance the prestige of the hospital pharmacy department, improve the quality of hospital pharmaceutical care services, and promote rational drug use. Nevertheless, certain barriers highlighted in this study should be addressed promptly.
Sections du résumé
Background
In China, the pharmacy departments of most hospitals have changed their main focus from drug procurement and distribution to providing pharmaceutical care services. Various regions of China have successively implemented the pilot Chief Pharmacist System (CPS) to help improve pharmaceutical care services and rational drug use in hospitals. This study was designed to explore the perspectives of pharmacists and government officials on CPS, including the advantages and barriers to the successful implementation of CPS.
Methods
A qualitative study, based on semi-structured interviews, was conducted from October 1, 2018 to March 1, 2019. The interview data were gathered from 18 pharmacy staff and government representatives working in five distinct regions of China using purposive sampling. A thematic analysis approach and NVivo version 12 Plus was utilized to code and analysis of all interviews.
Results
Five broad themes were identified: the role of the chief pharmacist; their attitudes toward the CPS; the advantages and results of the CPS; the barriers toward CPS; and their suggestions toward CPS. Most of the participants believed that the chief pharmacist played a vital role in a hospital. Under CPS, the hospital pharmacy department pays more attention to prescription review, medication monitoring, and pharmaceutical consultation. However, an insufficient number of pharmacy personnel, unclear authority, and inadequate salaries were the main barriers to the implementation of the CPS.
Conclusion
The attitudes of most of the participants were found to be positive toward CPS in China. The CPS can enhance the prestige of the hospital pharmacy department, improve the quality of hospital pharmaceutical care services, and promote rational drug use. Nevertheless, certain barriers highlighted in this study should be addressed promptly.
Identifiants
pubmed: 35784261
doi: 10.3389/fpubh.2022.895649
pmc: PMC9240424
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
895649Informations de copyright
Copyright © 2022 Yang, Li, Hayat, Zhai, Liu, Chen, Saeed, Chang, Li, Du, Xu, Wen and Fang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Circulation. 2009 Mar 17;119(10):1442-52
pubmed: 19289649
PLoS One. 2014 Feb 12;9(2):e87576
pubmed: 24533058
Eur J Hosp Pharm. 2017 Sep;24(5):258-265
pubmed: 31156955
Res Social Adm Pharm. 2019 Mar;15(3):321-329
pubmed: 29731375
PLoS One. 2018 Feb 8;13(2):e0192332
pubmed: 29420640
Eur J Hosp Pharm. 2018 Jan;25(1):2-5
pubmed: 31156977
Drug Metab Pers Ther. 2015 Dec;30(4):215-30
pubmed: 26457791
Health Policy Plan. 2019 Sep 1;34(7):483-491
pubmed: 31363744
BMC Med Inform Decis Mak. 2018 Jan 11;18(1):4
pubmed: 29325555
J Nepal Health Res Counc. 2018 Mar 13;16(1):36-42
pubmed: 29717287
Front Pharmacol. 2020 Jan 10;10:1520
pubmed: 31998124
Trop Med Int Health. 2017 Feb;22(2):180-186
pubmed: 27865024
Adv Exp Med Biol. 2021;1318:605-622
pubmed: 33973201
Value Health. 2014 Nov;17(7):A790
pubmed: 27202950
PLoS One. 2016 Nov 3;11(11):e0165707
pubmed: 27812177
Health Care Manag Sci. 2019 Sep;22(3):462-474
pubmed: 30868325
J Adv Pharm Technol Res. 2016 Jul-Sep;7(3):70-4
pubmed: 27429924
Int J Environ Res Public Health. 2019 May 05;16(9):
pubmed: 31060262
BMC Health Serv Res. 2022 Jan 5;22(1):28
pubmed: 34986824
PLoS One. 2018 Oct 22;13(10):e0206115
pubmed: 30346979
Int J Clin Pharm. 2021 Dec;43(6):1546-1554
pubmed: 34121156
Am J Hosp Pharm. 1982 Sep;39(9):1487-90
pubmed: 7137184
PLoS One. 2016 Sep 14;11(9):e0162795
pubmed: 27627811
Rev Panam Salud Publica. 2004 Mar;15(3):168-75
pubmed: 15096289
Res Social Adm Pharm. 2016 Sep-Oct;12(5):756-71
pubmed: 26626591
Eur J Hosp Pharm. 2022 Mar;29(e1):e46-e51
pubmed: 33789988
Saudi Med J. 2012 Jul;33(7):756-62
pubmed: 22821310
Pharm Pract (Granada). 2018 Oct-Dec;16(4):1396
pubmed: 30637036
BMC Health Serv Res. 2017 Mar 1;17(1):172
pubmed: 28249578
Health Policy Plan. 2017 Mar 1;32(2):225-235
pubmed: 28207051
Res Social Adm Pharm. 2011 Mar;7(1):51-63
pubmed: 21397881
Int Health. 2017 Sep 1;9(5):317-324
pubmed: 28911128
Bull World Health Organ. 2018 Dec 1;96(12):843-852
pubmed: 30505032
Pharm Pract (Granada). 2018 Jan-Mar;16(1):1121
pubmed: 29619140
Hepatobiliary Surg Nutr. 2020 Dec;9(6):771-773
pubmed: 33299831
Health Aff (Millwood). 2015 Aug;34(8):1391-8
pubmed: 26240254
Trop Doct. 2000 Jan;30(1):3-5
pubmed: 10842509
Int J Clin Pharm. 2016 Apr;38(2):271-9
pubmed: 26739130
J Eval Clin Pract. 2017 Dec;23(6):1482-1488
pubmed: 28990319
Int J Pharm Pract. 2017 Oct;25(5):343-350
pubmed: 27774716
Am J Health Syst Pharm. 2016 Mar 1;73(5):307-14
pubmed: 26896503
BMC Health Serv Res. 2018 Mar 27;18(1):218
pubmed: 29587742
Adm Policy Ment Health. 2015 Sep;42(5):533-44
pubmed: 24193818
Int J Health Plann Manage. 2018 Oct;33(4):e918-e929
pubmed: 29989204
Qual Quant. 2018;52(4):1893-1907
pubmed: 29937585
Int J Clin Pharm. 2020 Feb;42(1):167-173
pubmed: 31919733
Bull World Health Organ. 2017 Dec 1;95(12):800-801
pubmed: 29200520
Artif Intell Med. 2015 Jun;64(2):147-58
pubmed: 25940855
Indian J Pharmacol. 2011 Sep;43(5):599-600
pubmed: 22022009
PLoS One. 2017 Nov 30;12(11):e0188354
pubmed: 29190816
JAMA Intern Med. 2018 Jun 1;178(6):782-789
pubmed: 29801079
J Clin Pharm Ther. 2018 Dec;43(6):888-894
pubmed: 30003561